Department of Neurology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Med Clin (Barc). 2023 Mar 10;160(5):187-192. doi: 10.1016/j.medcli.2022.06.020. Epub 2022 Aug 10.
Multiple sclerosis (MS) is an immune-mediated disease that has been related to several risk factors such as various viral infections. We carried out this study in order to establish a relationship between COVID-19 infection and MS severity.
In a case-control study, we recruited patients with relapsing-remitting multiple sclerosis (RRMS). Patients were divided into two groups based on positive COVID-19 PCR at the end of the enrollment phase. Each patient was prospectively followed for 12 months. Demographical, clinical, and past medical history were collected during routine clinical practice. Assessments were performed every six months; MRI was performed at enrollment and 12 months later.
Three hundred and sixty-two patients participated in this study. MS patients with COVID-19 infection had significantly higher increases in the number of MRI lesions (p: 0.019, OR(CI): 6.37(1.54-26.34)) and EDSS scores (p: 0.017), but no difference was found in total annual relapses or relapse rates. COVID-19 infections were positively correlated with EDSS progression (p: 0.02) and the number of new MRI lesions (p: 0.004) and predicted the likelihood of the number of new MRI lesions by an odds of 5.92 (p: 0.018).
COVID-19 may lead to higher disability scores in the RRMS population and is associated with developing new Gd-enhancing lesions in MRI imaging. However, no difference was observed between the groups regarding the number of relapses during follow-up.
多发性硬化症(MS)是一种免疫介导的疾病,与多种危险因素有关,如各种病毒感染。我们进行这项研究是为了确定 COVID-19 感染与 MS 严重程度之间的关系。
在一项病例对照研究中,我们招募了复发缓解型多发性硬化症(RRMS)患者。根据在入组阶段末 COVID-19 PCR 阳性结果,将患者分为两组。每位患者前瞻性随访 12 个月。在常规临床实践中收集人口统计学、临床和既往病史。每 6 个月进行评估;在入组时和 12 个月后进行 MRI 检查。
共有 362 名患者参与了这项研究。COVID-19 感染的 MS 患者的 MRI 病变数量(p:0.019,OR(CI):6.37(1.54-26.34))和 EDSS 评分(p:0.017)显著增加,但总年度复发率或复发率无差异。COVID-19 感染与 EDSS 进展(p:0.02)和新 MRI 病变数量(p:0.004)呈正相关,新 MRI 病变数量的可能性比为 5.92(p:0.018)。
COVID-19 可能导致 RRMS 人群的残疾评分更高,并与 MRI 成像中新的 Gd 增强病变的发展相关。然而,在随访期间,两组之间的复发次数没有差异。